09:55 AM EDT, 06/10/2026 (MT Newswires) -- Danaher ( DHR ) said Wednesday it has completed its acquisition of Masimo ( MASI ) , a speciality diagnostics provider of pulse oximetry and other patient monitoring solutions.

Masimo ( MASI ) will continue to operate under its own brand as a stand-alone operating company within Danaher's ( DHR ) Diagnostics segment.

Masimo's ( MASI ) common stock has ceased trading on the Nasdaq Stock Market and the company is now a wholly owned subsidiary of Danaher ( DHR ), according to a statement.

Additionally, Danaher ( DHR ) said that there is no change to its Q2 and 2026 guidance, excluding the expected contribution from Masimo ( MASI ).

The company said it does not expect a material contribution from Masimo ( MASI ) in Q2 and plans to update full-year 2026 guidance with its Q2 earnings release to incorporate Masimo's ( MASI ) expected contribution.

For Q2, Danaher ( DHR ) expects adjusted core revenue to increase in the low single-digit percent range year-over-year. For 2026, the company expects adjusted diluted EPS of $8.35 to $8.55. Analysts expect 2026 EPS of $8.44.

Price: 186.97, Change: -1.53, Percent Change: -0.81